FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC
$ICPT
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/13/2023 | $8.00 → $19.00 | Sell → Buy | H.C. Wainwright |
6/29/2023 | $12.00 → $18.00 | Hold → Buy | Canaccord Genuity |
5/23/2023 | Buy → Hold | Needham | |
5/22/2023 | $8.00 | Neutral → Sell | H.C. Wainwright |
5/17/2023 | Outperform → Mkt Perform | Raymond James | |
3/8/2022 | $31.00 → $29.00 | Hold | Canaccord Genuity |
3/3/2022 | $22.00 → $16.00 | Sector Perform | RBC Capital |
3/3/2022 | $30.00 → $25.00 | Buy | Needham |